Powerful clinical efficacy across patient groups
In 1st line with letrozole
In an updated non-prespecified PFS analysis of PALOMA-2, 1st line IBRANCE® + letrozole demonstrated PFS improvements vs placebo + letrozole in patients with bone-only disease*†2
- In PALOMA-2, 23.2% of patients treated with IBRANCE® + letrozole had bone-only disease2
Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.
Adapted from Rugo H, et al. 2019.2
Data cut-off date: May 31, 2017.
In the same PFS analysis:
30.4 months mPFS with IBRANCE + letrozole vs 16.5 months with placebo + letrozole (HR=0.51) in patients with a single disease site, who, together with bone-only patients, are considered patients with low disease burden*†2
*Evaluated according to RECIST Version 1.1.3 †Updated follow-up of the primary analysis of PALOMA-2: 37.6 months in the IBRANCE + letrozole arm.2
CI = confidence interval; HR = hazard ratio; LET = letrozole; mPFS = median progression-free survival; n = number of patients; NE = not estimable; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors.
- IBRANCE® Summary of Product Characteristics.
- Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729.
- Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
©2020 Pfizer. All rights reserved. PP-IBR-IRL-0501 Date of Preparation: March 2022 Legal Category: S1A